PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31308200-0	2019	Febuxostat Desensitization in a Patient with Previous Stevens-Johnson Syndrome and HLA-B*58:01 Genotype.	Febuxostat	0-10	major histocompatibility complex, class I, B	Homo sapiens	83-88	
33722946-2	2021	Gout is the most common inflammatory arthritis1, historically poorly managed, and is arguably the only one of the inflammatory arthritides that is curable with appropriate urate-lowering therapy (ULT)2 Whereas febuxostat has been shown to be a more effective ULT3, allopurinol has been the cornerstone of treatment for decades; however, allopurinol is problematic in the elderly, those with renal impairment, and those who carry the HLA-B*5801 antigen who are primarily of Asian origin.	Febuxostat	210-220	major histocompatibility complex, class I, B	Homo sapiens	433-438	
27916277-5	2017	Those who tested positive for HLA-B*5801 received febuxostat.	Febuxostat	50-60	major histocompatibility complex, class I, B	Homo sapiens	30-35	
29642234-7	2018	The evaluation of four models with or without genetic screening and management of allopurinol or febuxostat indicated that the HLA-B*5801 screening had significant cost benefit for clinical management.	Febuxostat	97-107	major histocompatibility complex, class I, B	Homo sapiens	127-132	
28957559-9	2017	Conclusion: Routine testing for HLA-B*58:01 in order to reduce the incidence of adverse drug reactions in patients being prescribed allopurinol for gout is unlikely to be cost-effective in the UK; however testing is expected to become cost-effective with reductions in the cost of genotyping, and with the future availability of cheaper, generic febuxostat.	Febuxostat	346-356	major histocompatibility complex, class I, B	Homo sapiens	32-37	
26365588-1	2015	WHAT IS KNOWN AND OBJECTIVE: Febuxostat is recommended as an alternative drug for gouty patients with a history of allopurinol hypersensitivity or carrying the HLA-B*5801 allele.	Febuxostat	29-39	major histocompatibility complex, class I, B	Homo sapiens	160-165	
26771445-0	2016	Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.	Febuxostat	28-38	major histocompatibility complex, class I, B	Homo sapiens	56-61	
26771445-9	2016	CONCLUSIONS: Febuxostat was more effective than allopurinol in reducing the serum urate levels of Han Chinese patients with gout or tophaceous gout who were HLA-B*5801 negative, without causing any serious skin reactions.	Febuxostat	13-23	major histocompatibility complex, class I, B	Homo sapiens	157-162	
26771445-10	2016	Febuxostat should be considered for treatment of Han Chinese patients with gout who are HLA-B*5801 negative.	Febuxostat	0-10	major histocompatibility complex, class I, B	Homo sapiens	88-93